Peer-review scientific medical journal


  • professor Dmitry A. Sychev, Doctor of Medical Sciences, Corresponding Member of RAS, Rector of Russian Medical Academy of Continuous Professional Education
    | WEB | ORCID | SCOPUS Author ID |


  • LLC “Bionika Media”


  • LLC “Bionika Media”

WEB official

Aims and Scope

"Farmateka" is peer-reviewed scientific and practical medical journal, intended for physicians, pediatricians, cardiologists, endocrinologists, gastroenterologists, pulmonologists, dermatologists, obstetricians, gynecologists, urologists, oncologists, neurologists, rheumatologists, and other doctors.

The "Farmateka" journal has been published since 1994. Starting with the first issues of the journal, information for practitioners about modern drugs, their therapeutic action, pharmacokinetics and pharmacodynamics, side effects are provided on its pages; the recent advances in medical science and technology, significant clinical studies of drugs, the results of international and Russian congresses and conferences are reported. Each issue contains news on the most relevant medical events and discoveries.

From 2002 to 2017, the editorial board was headed by Corresponding Member of RAMS Yury B. Belousov, and the board included a number of leading Russian specialists. Number of readers of the journal extends - practitioners, heads of medical institutions and universities, research institutes, heads of departments, students and external doctorate students read the publication.

The Editorial Board of the “Farmateka” journal includes the leading Russian specialists in the main areas of clinical medicine - 40 doctors of medical sciences, including 8 academicians and 9 corresponding members of the Russian Academy of Sciences. All of them are actively involved in the creation of the journal and confirmed their consent to join the Editorial Board.

All issues of the journal are thematic and are dedicated to specific areas of clinical medicine. Since 2018, the journal comes out with the periodicity of 14 issues per year. The average volume of full-color issue is 96–144 pages. The circulation of the journal exceeds 25 thousand copies. Circulation certified by the National Circulation Service. The “Farmateka” journal is sent by subscription and distributed on medical congresses, conventions and conferences, and on training cycles for doctors and students in the territory of the Russian Federation.

Acting Editor-in-Chief: Victor V. Fomin - Doctor of Medical Sciences, Professor, Corr. Member of RAS, Chief External Expert in General Practice of the Moscow Healthcare Department, Head of the Department of Faculty Therapy № 1 and Director of the V.N. Vinogradov Faculty Therapy Clinic; Vice Rector for Clinical Care of the Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Health of the Russian Federation, Moscow.

The journal is published on the following main subjects: Pediatrics, Gastroenterology/Hepatology, Obstetrics and Gynecology, Uronephrology, Pulmonology/ENT Diseases, Endocrinology, Neurology/Rheumatology, Oncology, Cardiology/Neurology, Therapy, Dermatology/Cosmetology, Allergology.

The “Farmateka” journal publishes original articles, clinical reviews, reviews and lectures on the most topical issues of pharmacotherapy, prepared by leading experts in relevant fields of medicine.

The “Farmateka” journal is intended to provide for readers - a wide range of doctors and medical scientists - with the most up-to-date information on the results of clinical studies and new, innovative diagnostic and treatment methods.

The journal is included in the list of publications recommended by the Higher Attestation Commission (HAC).

Every year, collection of selected scientific articles on endocrinology "Modern aspects of pharmacotherapy of endocrine diseases" edited by M. B. Antsiferov (Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Natural Sciences, Deputy Director of the Institute of Diabetes, Head of the Diabetic Foot Unit of the ERC; Chief Endocrinologist of the Moscow Healthcare Department, Chief Physician of the Endocrinology Dispensary of the Moscow Healthcare Department, Moscow, Russia) is published as part of the “Farmateka” journal. The collection is arranged to coincide with the Moscow City Congress of Endocrinologists.

'Farmateka' journal is included in the in the list of publications recommended by the Higher Attestation Commission (HAC) for the following medical sciences:

  • 14.01.01 - Obstetrics and Gynecology (Medical Sciences);
  • 14.01.02 - Endocrinology (Medical Sciences);
  • 14.01.05 - Cardiology (Medical Sciences);
  • 14.01.11 - Nervous Diseases (Medical Sciences);
  • 14.01.25 - Pulmonology (Medical Sciences);
  • 14.01.03 - Diseases of the Ear, Nose and Throat (Medical Sciences);
  • 14.01.04 - Internal Diseases (Medical Sciences);
  • 14.01.08 - Pediatrics (Medical Sciences);
  • 14.01.10 - Skin and Sexually Transmitted Diseases (Medical Sciences);
  • 14.01.12 - Oncology (Medical Sciences);
  • 14.01.22 - Rheumatology (Medical Sciences);
  • 14.01.28 - Gastroenterology (Medical Sciences).

Current Issue

Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

Vol 29, No 14 (2022)


Vsutpitel'noe slovo
Sychev D.A.
Pharmateca. 2022;29(14):5-5
pages 5-5 views
- -.
Pharmateca. 2022;29(14):6-9
pages 6-9 views
Discoid lupus erythematosus
Yusupova L.A., Garayeva Z.S., Yunusova E.I., Mavlyutova G.I., Fatkhutdinova L.I.
The article presents data on discoid lupus erythematosus (DLE), characterized by a staged development of erythematous rash, follicular hyperkeratosis and cicatricial atrophy. Disease manifestations are associated with significant discomfort due to frequent occurrence on the face, scalp, ears; appearance of scarring. Factors that increase the likelihood of developing DLE include skin phototype I, drug intolerance, prolonged sun exposure, exposure to cold and wind, a history of chronic infection, and female gender. Ultraviolet radiation, dysregulation of the function of cytotoxic T-lymphocytes, dendritic cells and natural killers are pathogenetic components of the disease. Currently, the treatment of patients is associated with certain difficulties and the likelihood of relapse after discontinuation of drugs or after repeated exposure to trigger factors, which significantly worsens their quality of life.
Pharmateca. 2022;29(14):10-14
pages 10-14 views
Overview of laser and phototherapy techniques for the treatment of onychomycosis
Surkichin S.I., Mayorov R.Y., Arabadzhyan M.I.
Onychomycosis occurs in 10-20% of the population. Among all types of pathology of the nail apparatus, nail mycosis is the most common and accounts for at least 50%. This disease is not only considered an aesthetic defect, but also leads to severe systemic complications, so the study of this problem is extremely important in modern medicine. Unfortunately, the use of classical therapy in the form of local or systemic antifungal agents often does not lead to the desired result, entails a lot of adverse consequences (for example, in the form of toxic damage to the kidneys and liver when using itraconazole), recurrence of the infection. Therefore, it is necessary to look for alternative methods that will eliminate toxic drugs or at least reduce their dosage. This article discusses laser and phototherapy techniques for the treatment of onychomycosis, such as CO2 laser, photodynamic therapy, ultraviolet radiation, Nd:YAG laser.
Pharmateca. 2022;29(14):15-20
pages 15-20 views
Laser therapy and phototherapy for rosacea
Matushevskaya Y.I.
Rosacea is a non-communicable dermatological disease of middle age that requires long-term and often life-long treatment. The debut of the disease begins with minor clinical manifestations, such as centrofacial transient erythema or conjunctivitis, which is not considered by patients as a need to see a doctor. Early therapy prevents chronicity of the process and the development of severe forms, such as papulopustular rosacea, ophthalmic rosacea and phimosis. One of the methods of rosacea therapy is physiotherapy, including laser therapy, cryotherapy, darsonvalization, electrophoresis, electrocoagulation, pulse therapy, inductothermy, phototherapy of vascular pathology, etc. This review presents the main mechanisms of the action of laser light on human skin and systematizes data on its use in various forms of rosacea.
Pharmateca. 2022;29(14):21-26
pages 21-26 views
Modern approaches to the treatment and prevention of fungal urinary tract infections
Sturov N.V., Popov S.V., Shmelkov I.Y.
Studies in recent years show an increase in the incidence of fungal urinary tract infection (UTI). The most common causative agents of fungal UTIs are representatives of the genus Candida. Antifungal therapy is indicated in case of the detection of fungi in the urine of patients with symptoms of UTI, immunocompromised patients, low birth weight newborns, and also before urological surgical interventions. For the treatment of urinary tract candidiasis, the use of drugs of the triazole group - amphotericin B and flucytosine is recommended. Fluconazole is the most common drug for treating fungal urinary tract infections. Unlike other azoles, fluconazole is available for oral administration, soluble in water, up to 80% of the drug is excreted unchanged by the kidneys, creating an effective concentration in the urine. The frequency of fluconazole-sensitive strains of fungal UTI pathogens is gradually decreasing. Therapy with fluconazole for fungal UTIs is recommended for 7-14 days. Prevention of fungal UTI in most cases does not require drug therapy. The basis for the prevention of the development of fungal UTI includes the correction of risk factors for the development of this disease: the timely removal or replacement of urinary drainage, the cessation of antibiotic therapy and the restoration of the passage of urine through the urinary tract.
Pharmateca. 2022;29(14):27-33
pages 27-33 views
Systematic review and meta-analysis: predictors of psoriatic arthritis
Pereverzina N.O., Kruglova L.S., Korotaeva T.V., Lila A.M.
Background. Psoriasis is a chronic systemic immune-inflammatory disease that affects not only the skin, but also the musculoskeletal system. According to epidemiological and clinical studies, every fourth patient with psoriasis develops psoriatic arthritis. Early diagnosis and early initiation of therapy allows to prevent the development of severe forms and disability. Identification of early predictors of psoriatic arthritis and referral of such patients for rheumatological examination may help to solve this problem. Methods. The existing literature was searched in the PubMed (MEDLINE), EMBASE and Google Scholar databases for 10 years up to 02/20/2021. The search for current registered trials was carried out in the clinical trial registries of the United States (Clinicaltrials. gov), China (Chinese Clinical Trial Registry) and the WHO International clinical trial registry platform. Statistical analyzes were prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) using Statistic SPSS 26.0 (US-manufactured). Meta-analysis was prepared using RevMan 5 software. Results. We identified 342 articles published up to February 20, 2021. After further analysis, irrelevant articles were excluded. A total of 35 articles were included in the review and analysis. psoriatic arthritis predictors include enthesitis, nail lesions, uveitis, and axial lesions. In addition, there are biomarkers for psoriatic arthritis. According to meta-analysis, a statistically significant increase in the risks of developing psoriatic arthritis by 1.52 times (95% C11.22-1.88) was noted in the presence of damage to the nail apparatus. In addition, not only the risks of developing psoriatic arthritis but also the chances of developing psoriatic arthritis increased with statistical significance by 2.76 times (95% CI: 1.94-3.92). Conclusion. Psoriasis and psoriatic arthritis are multifactorial diseases with sharply reduced quality of life of patients, the possible development of severe forms and disability. Therefore, early diagnosis of such conditions is very important. Nail damage can be considered as predictors of psoriatic arthritis, so it is very important for dermatologists to evaluate not only smooth skin. Further research is needed to better understand this issue.
Pharmateca. 2022;29(14):34-40
pages 34-40 views
The effectiveness of the combined use of topical glucocorticosteroid and photodynamic therapy in vulvar lichen sclerosus
Surkichin S.I., Kruglova L.S., Apolikhina I.A.
Objective. Evaluation of the effectiveness of photodynamic therapy in the treatment of vulvar lichen sclerosus (VLS), taking into account the data of the visual analogue scale using various methods of therapy. Methods. The study included 45 women with a confirmed diagnosis of VLS. Depending on the therapy, the groups are divided into subgroups. Group 1A - patients with VLS who were prescribed topical glucocorticosteroid (tGCS), group 1B - patients with VLS who were prescribed photodynamic therapy (PDT), group 1C - patients with VLS who were prescribed combined treatment: tGCS + PDT. Results. Data obtained indicate that combination therapy with tGCS and PDT is the method of choice for the treatment of vulvar lichen sclerosus.
Pharmateca. 2022;29(14):41-47
pages 41-47 views
Skin barrier disorders in atopic dermatitis: from the history of the study to the development of «emollients plus»
Kruglova L.S., Zaslavsky D.V., Pereverzina N.O., Sokolovskaya Y.A.
Background. Modern clinical guidelines for the treatment of patients with atopic dermatitis (AD) include the mandatory use of specialized dermatocosmetics - emollients (recommendation grade A), regardless of the severity of the process and the period of the disease (exacerbation, remission). During an exacerbation of AD, emollients are prescribed as part of complex therapy; during an remission, they can be used as a monotherapy. Objective. Evaluation of the effectiveness of complex therapy in patients with atopic dermatitis using a topical glucocorticosteroid (activity class 2) and Atopi Control products. Methods. The study included 27 patients aged 10 to 48 years (mean age 16.2±4.3 years) with AD in the acute stage with severe symmetrical erythema and itching on the forearms (modified SCORing Atopic Dermatitis (SCORAD) index 10.0±2.0). In accordance with clinical recommendations, all patients were prescribed a topical glucocorticosteroid (GCS) of the activity class 2, Atopi Control1 lotion 2 times a day on the right forearm and basic emollient2 2 times a day on the left forearm. After the exacerbation was removed (after 2 weeks), GCS was canceled, and patients continued to use emollients for 12 weeks. The number of relapses and the severity of symptoms at each exacerbation (local SCORAD) on the right and left hands were recorded, taking into account the presence of erythema, exudation, rash, excoriation, lichenification, and dry skin. The intensity of itching in the study area was assessed by patients using a visual analog scale (VAS) from 0 (no itching) to 10 (severe itching). Results. As a result of therapy, after 2 weeks the local SCORAD index decreased by 68%. In the control area (basic emollient application), the reduction in local SCORAD after 2 weeks was 45%. The number of relapses (persistent erythema for 3 or more days) in the Atopi Control group was 64% lower than in the basic emollient group (8 versus 22 reported exacerbations in 12 weeks), the severity of itching during exacerbations was also significantly lower in the Atopi Control group. All patients noted the comfort of using Atopi Control products, their excellent organoleptic properties. Conclusion. The inclusion of Atopi Control in therapy provides control over the course of AD: it quickly reduce the symptoms of the disease during exacerbations, reduce the number of relapses and their severity.
Pharmateca. 2022;29(14):48-54
pages 48-54 views
Mental status and quality of life in pediatric patients with alopecia areata: a cross-sectional (questionnaire) study
Dogov A.M., Murashkin N.N., Ambarchyan E.T., Nezhvedilova R.Y., Fedorov D.V.
Background. Alopecia areata (AA) is the most common autoimmune disease and the second most common hair loss disorder after androgenetic alopecia. To date, in our country there is not enough information on the prevalence of symptoms of psychological disorders in pediatric patients with AA. Objective Determination of the prevalence of psychological and mental disorders in patients with AA and assessment of the quality of life (QoL) of patients with AA in childhood. Methods. A cross-sectional (questionnaire) study was carried out at the Department of Dermatology with the Group of Laser Surgery, Center for Pediatric Dermatology and the Laboratory of Children’s Skin Pathology, National Medical Research Center for Children’s Health. The study was conducted from 07/15/2021 to 07/15/2022. Data collection came from the created National Registry for Children with AA. A total of 116 patients were included in the study. The mean age of the patients was 9.3±2.8 years. The evaluation was carried out using Russian-language questionnaires (mental scales). Results. In the course of our study, it was found that a decrease in QoL was observed in 63.79% of children with AA according to the AAQL scale and 72.42% of children according to the AASIS scale. Clinically pronounced symptoms of anxiety and depression (according to the HADS scale) were detected in 23.27 and 22.41% of patients in the study group. Conclusion. Being a chronic relapsing disease, AA has a pronounced negative effect on the QoL of patients. The disease not only has a severe psychological impact, but also causes a noticeable disruption in the social life of children.
Pharmateca. 2022;29(14):55-61
pages 55-61 views
The key role of an emollient with an active antipruritic component in the strategy for improving the quality of life of patients of the older age group with itching against the background of xerosis
Kruglova L.S., Shatokhina E.A.
Background. In patients of the older age group, physiological xerosis of the skin is caused by structural and qualitative changes in the epidermis and dermis, and “fragility" - by decrease in the activity of the immune system in the epidermis. Skin xerosis can cause itching, which negatively affects quality of life (QoL). Objective. Evaluation of the effectiveness of Neotanin Comfort Plus cream in elderly patients with skin xerosis and itching. Methods. An open non-comparative study with 2-week follow-up period was carried out. 40 patients aged 60 to 74 years with skin xerosis and itching were included in the study. For two weeks, all patients used Neotanin Comfort Plus cream as a skin care product 1-2 times a day, and also during the day as needed. Results. As a result of the use of Neotanin Comfort Plus cream, the corneometry indicator increased by 16,6% (localization on the back) and by 12.3% (shin area), the indicator of transepidermal water loss decreased by 13.8% and 10.1%, respectively. The MAS indicator (itching) decreased by 85.1%, the total QoL index improved by 77.6%. All patients noted excellent or good organoleptic properties of the cream and the comfort of its use. Thus, 97.5% of patients rated the comfort/convenience during application as excellent or good, 95% of patients noted an excellent/good feeling after applying the cream, 95% - excellent absorption of the cream. Conclusion. Neotanin Comfort Plus cream can be recommended for patients with skin itching against the background of xerosis.
Pharmateca. 2022;29(14):62-68
pages 62-68 views
The effectiveness of combined treatment of rosacea using neodymium laser and photodynamic therapy
Bakulev A.L., Bakuleva M.V.
Background. The treatment of patients with rosacea presents a problem due to the lack of effectiveness of available therapeutic agents and methods, the need to use them for a long time and possible poor tolerance. The combined use of a vascular laser and photodynamic therapy, which has anti-inflammatory and antimicrobial effects, may be a promising direction in the treatment of patients suffering from the papulopustular subtype of this pathology. Objective. Evaluation of the efficacy and safety of combined treatment of patients with papulopustular subtype of rosacea using a neodymium laser and photodynamic therapy. Methods. 35 patients with papulopustular subtype of rosacea were followed-up. In the complex of therapeutic measures, laser therapy using a neodymium laser DEKA Motus AY (2 procedures) and photodynamic therapy REVIXAN with a photosensitizer chlorin E6 were consistently used (5 procedures per course). In dynamics, the number of inflammatory elements (papules, pustules), IGA index, der-matological life quality index DLQI, and side effects of therapy were evaluated. Results. In patients receiving laser therapy and photodynamic therapy, compared with the control group receiving topical therapy with metronidazole, a decrease in the key manifestations of the disease (the severity of background centrofacial erythema; the number and size of inflammatory papules and pustules) was noted at an earlier time. Serious side effects of the therapy were not registered. Conclusion. Thus, the use of instrumentsl methods of therapy for rosacea significantly improves the results of therapy for this disease in patients in the form of a significant decrease in the severity of centrofacial permanent erythema, the number and size of inflammatory papules and pustules.
Pharmateca. 2022;29(14):69-72
pages 69-72 views
Features of the cytokine status, lipid peroxidation and the state of the antioxidant system in patients with true eczema
Novikova L.A., Dontsova E.V., Chernov A.V., Saurina O.S., Dontsov V.G., Pogodaeva T.I.
Objective. Evaluation of the features of the blood cytokine status, oxidative processes and the state of the antioxidant system in patients with true eczema in the acute stage. Methods. The study included 131 patients (mean age 58.7±3.6 years). Serum levels of pro-inflammatory cytokines - interleukins (IL) IL-10, -2, -6, IFN-y, TNF-а and anti-inflammatory cytokine IL-10, as well as indicators characterizing the state of oxidative stress and antioxidant protection were determined by enzyme immunoassay. Results. It has been established that during exacerbation of true eczema in patients, increased production of a complex of pro-inflammatory ILs, as well as IFN-y and TNF-а, was detected, accompanied by a decrease in the anti-inflammatory IL-10 level. Along with this, activation of the processes of lipid peroxidation (LPO) and insufficient production of the components of the antioxidant system were noted. Conclusion. Direct correlation between the activity of the system of pro-inflammatory cytokines and the severity of LPO processes was established; it must be taken into account when planning a complex of therapeutic measures.
Pharmateca. 2022;29(14):73-77
pages 73-77 views
The effectiveness of cryolipolysis in excess local fat deposits
Surkichin S.I., Kruglik E.V.
Objective. Evaluation of the effectiveness and safety of cryolipolysis based on a comparative analysis of soft tissue ultrasound data. Methods. This study presents the results of using cryolipolysis for excess localized fat deposits based on ultrasound data. The study group included 62 patients with complaints of excessive local fat deposits. The first control group consisted of 10 patients who followed the dietitian’s recommendations. The first main group included 8 patients who underwent cryolipolysis of one anatomical area, with a total area of about 160 cm2, or two anatomical areas, with an area of 80 cm2 each. The second main group included 24 patients with excessive local fat deposits, who underwent 2 consecutive cryolipolysis procedures according to the Treatment to Transformation (T2T) protocol. Results. Efficiency in groups where cryolipolysis was used was significantly higher. At the same time, in men, the effect occurred later than in women - only after 10 weeks. Conclusion. In general, women tolerated the procedure more easily, less often complained of soreness, swelling, and hyperesthesia at the site of the procedure.
Pharmateca. 2022;29(14):78-81
pages 78-81 views
Secondary infection in allergic dermatoses, variety of forms and individual choice of therapy
Tamrazova O.B., Stadnikova A.S., Taganov A.V., Glukhova E.A., Sukhotina A.G., Sadovnikova A.M.
Background. According to the incidence rate in pediatric practice, patients with allergic dermatosis complicated by a secondary infection rank first and account for 30-40% of the total number of visits. The most common manifestations are atopic dermatitis with symptoms of secondary infection, microbial eczema, advanced scabies complicated by pyoderma, seborrheic dermatitis (eczema), paratraumatic eczema, contact-allergic dermatitis complicated by secondary infection. Objective. Evaluation of the therapeutic effects and safety of using Levomekol medicinal ointment in the routine pediatric clinical practice in children with secondarily infected dermatoses. Methods. Non-interventional prospective study of the use of Levomekol® ointment in routine clinical practice in children with dermatoses complicated by secondary infectionwas conducted on the basis of the Children’s City Clinical Hospital n.a. Z.A. Bashlyaeva. 35 patients who received combined therapy with Levomekol® ointment and topical glucocorticosteroids - GCS (methylprednisolone aceponate, betamethasone dipropionate, hydrocortisone acetate, fluocinolone acetonide) were followed-up. The primary endpoint of efficacy was the relief of wound infection clinically characterized as the absence of edema, hyperemia, and purulent discharge at the sites of infection. Secondary efficacy criteria: reduction in the area of the site of infection by visual assessment using the results of photofixation; clinical improvement according to the CGI-I scale and efficiency index according to the CGI-E scale (in points); CGI-S score (disease severity); reduction of pain in the area of the site of infection (wound) by VAS by 2 or more points or by 50% of the initial value in points. Results. Achievement of the primary end point when using the drug Levomekol® (no edema, hyperemia and purulent discharge in the area of the site of infection) in patients with secondarily infected dermatoses was registered earlier than the 14th day. Additional administration of systemic drugs during treatment was not required. When evaluating secondary efficacy criteria, it was noted that Levomekol® demonstrated 90-100% efficacy according to all studied criteria in the treatment of secondarily infected dermatoses by the 3-7th day of therapy, as well as absolute safety and good tolerability by patients. Conclusion. The studied drug Levomekol® demonstrated a pronounced anti-inflammatory effect, high efficiency in the relief of wound infection, a high safety profile and good tolerance by patients. The method of combined use of Levomekol ointment and topical corticosteroids in the treatment of allergic dermatosis complicated by a secondary infection has many advantages: the possibility of selective selection of the «molecule» of corticosteroids, regulation of «priorities» antibiotic or corticosteroids; the presence of methyluracil in the composition of Levomekol® ointment enhances regeneration in case of cracks and excoriations.
Pharmateca. 2022;29(14):82-90
pages 82-90 views
Historical background of clinical and preclinical studies of drugs for medical use
Ter-Ovakimyan A.A., Kruglova M.S.
In the course of the formation of modern society, the legal field of activity associated with conducting research with the participation of people for various purposes and motives, including the search for drugs and substances for the prevention and treatment of various diseases, has undergone many changes. At the moment, regulatory documents, tools and governing bodies have been developed to successfully regulate this process.
Pharmateca. 2022;29(14):91-93
pages 91-93 views
Amelanotic melanoma: current state of the problem
Titov K.S., Glumsky V.V., Zapirov M.M., Neretin E.Y., Grekov D.N.
Amelatonic melanoma is a rare and aggressive form of melanoma. This is a difficult oncological diagnosis that requires increased doctor’s alertness, and the need for adequate diagnosis and treatment. The prevalence of amelatonic melanoma among other malignant neoplasms of the skin is about 2-8%. Such differences in the epidemiological data are attributable, on the one hand, to the difficulties in diagnosing this tumor, and on the other hand, to the incorrect use of the term “amelatonic melanoma" by patients with hypopigmented melanoma. Despite the absence of specific markers, the use of modern diagnostic methods makes it possible to detect cases of amelatonic melanoma and start antitumor treatment in a timely manner. In establishing an accurate diagnosis, an important role is played by the clinical experience of an oncologist or dermatovenereologist conducting the initial examination, his proficiency in dermatoscopy, which is one of the main methods for the primary diagnosis of malignant skin tumors. Also, the professionalism and readiness of the pathomorphological laboratory, its equipment with reagents that allow for appropriate immunohistochemical studies, in particular for Melan A, S-100, HMB-45, tyrosinase, are of great importance. Currently, there is a small number of scientific studies aimed at studying rare skin malignancies.
Pharmateca. 2022;29(14):94-99
pages 94-99 views
Psoriasis, metabolic syndrome and COVID-19: a case report
Vladimirova I.S.
The COVID-19 pandemic that broke out in 2020 is still having a huge impact on dermatological practice. Patients suffering from moderate and severe forms of psoriasis, among which the majority require long-term immunosuppressive therapy, cause significant concern among dermatologists. It is now known that psoriasis may be a predisposing factor in the severe course of COVID-19, as systemic inflammation in psoriasis and comorbid conditions can cause the development of a cytokine storm and an increased risk factor for an unfavorable outcome. To date, the accumulated knowledge to determine the extent of the impact of COVID-19 on infected psoriasis patients receiving systemic treatment is insufficient. Practicing dermatologists are faced with the question of the possibility and safety of continuing systemic biological therapy in patients with psoriasis with comorbid pathology and COVID-19. The article presents the observation of a patient with severe plaque psoriasis, metabolic syndrome and COVID-19 who received systemic biological therapy. Keywords: psoriasis, COVID-19, cardiovascular complications, targeted therapy for psoriasis
Pharmateca. 2022;29(14):100-103
pages 100-103 views
Injectable lipolytics and complications from their use
Ikonnikova E.V., Manturova N.E., Kruglova L.S., Rodina A.L.
Background. There are a lot of non-certified products on the cosmetology market, and there is no tendency to reduce the share of such low-quality drugs at the moment. It is important to be able to correctly diagnose and treat patients with complications after injectable lipolytic therapy with non-certified drugs. The article discusses the terminology, experience of injectable lipolysis, classification of lipolytics, the mechanism of action of phosphatidylcholine and deoxycholic acid, indications and contraindications for their use, topography of the method of injectable lipolysis, an overview of the most widely used lipolytics, their side reactions and complications. Description of the clinical case. A description of a clinical case of the development of an inflammatory reaction after injectable lipolytic therapy (non-certified in the Russian Federation) with an analysis of the tactics of correction the complication is given. This clinical case demonstrates the importance of using certified products. The objective reasons for the development of complications, in addition to the poor quality of the injected drug, may be inadequate injection technique (too close location of individual injections and their insufficient depth), the introduction of a large volume of lipolytic mixture, as well as non-compliance with the asepic and antiseptic regulations.
Pharmateca. 2022;29(14):104-110
pages 104-110 views
Difficulties in diagnosis and treatment of primary skin lymphoma (clinical case)
Okhanova E.V., Shatokhina E.A., Sherstnev A.A., Kovrigina A.M.
Differential diagnosis of primary lymphoma and pseudolymphoma of the skin is an urgent issue that requires the attention of dermato-venereologists, hematologists, and oncologists. Skin pseudolymphoma is a reactive dermatosis that occurs in response to exogenous and endogenous influences, and primary skin lymphoma is a malignant proliferation of lymphocytes. The diagnosis is difficult due to the clinical and histological similarity of these nosologies. Diagnosis of primary skin lymphoma requires the interaction of doctors of different specialties. The presented clinical case demonstrates the result of a successful interdisciplinary collaboration of dermatovenereologists, pathologists, hematologists and oncologists.
Pharmateca. 2022;29(14):112-115
pages 112-115 views
Experience with phage monotherapy in a patient with atopic dermatitis: a clinical case
Gladkov S.F., Perevoshchikova N.K., Pichugina Y.S.
Background. Being one of the most common childhood allergic dermatosis, atopic dermatitis (AD) is realized under the influence of environmental factors in children at risk. Environmental conditions determine both the initiation of the formation of the atopic phenotype and the course of the disease itself. Understanding the complex mechanisms of evolution of the atopic march opens up opportunities to control and manage it. Description of the clinical case. A case of the onset of AD in a child aged 8 weeks is presented, selective phage decontamination (SPD) as a monotherapy for 16 days made it possible to completely stop the skin syndrome. Conclusion. The use of phage therapy in the treatment of children with AD, even in the form of monotherapy, can significantly influence the course of the disease and exclude the possibility of recurrence.
Pharmateca. 2022;29(14):116-119
pages 116-119 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies